Sunday 18 October 2026 Export SSKN’s income statement to Excel — free account

Strata Skin Sciences, Inc.

Strata Skin Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.7 million, down 8.54% from fiscal 2024. In the quarter to December 2025, revenue fell 2.97%, EPS grew 111.5%, free cash flow fell 376.9% and total debt rose 1.03%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.00 0.00 NaN

Follow SSKN

Alert me

Market cap: $1.0M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 5/9
Altman Z: −11.48
Beneish M: −3.33
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01

Total sells 0.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 15.49%

Capital & Financial Ratios $m

Market Cap 1.01

Revenue 30.70

Net Income (6.26)

Free Cash Flow (4.26)

Net Debt 7.44

Current Ratio 0.58

Debt/Equity 5.28

P/E ratio 0.00

Fwd P/E (0.14)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (648.25%)

Next Y EPS Growth 28.33%

Next Y revenue growth 6.79%

Next 5Y EPS Growth 25.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 73.18%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	7	8	9	8
Receivables	4	4	5	4
Inventory	3	3	2	3
Other	—	—	—	—
	15	16	17	16

	2022	2023	2024	2025
Payables	3	3	2	3
ST’ Debt	0	—	—	15
Other	0	0	1	—
	13	12	13	27

Compound Annual Growth %

	10y	5y	3y
Sales	5.20%	5.86%	(5.32%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(15.72%)	(35.42%)	(48.93%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	7	8	7	9	31
’24	7	8	9	10	34
’23	8	8	9	9	33
’22	7	9	9	11	36
’21	6	7	8	9	30
’20	7	4	6	7	23

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	(1)	(2)	0	0	(3)
’24	(1)	1	0	1	0
’23	(1)	1	(2)	1	(1)
’22	0	0	(1)	0	(1)
’21	0	0	0	1	2
’20	1	1	1	0	2

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	(1)	(2)	(1)	(1)	(4)
’24	(2)	0	0	0	(1)
’23	(3)	(1)	(2)	0	(6)
’22	(1)	(1)	(1)	(2)	(5)
’21	(1)	0	(1)	0	(2)
’20	1	1	(1)	0	0

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	(0.58)	(0.60)	(0.36)	0.13	(1.35)
’24	(1.00)	(0.03)	(0.53)	(1.13)	(2.65)
’23	(0.80)	(0.90)	(0.30)	(1.10)	(3.10)
’22	(0.70)	(0.50)	(0.30)	(0.05)	(1.60)
’21	(0.70)	0.30	(0.15)	(0.20)	(0.80)
’20	(0.30)	(0.50)	(0.40)	(0.10)	(1.30)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.14	1.06	1.09	1.65	0.75	1.30	0.74	0.26	2.51	1.18	Analyst estimates 2026–2028 Powerpack
	High	7.65	5.40	3.88	3.43	2.53	2.84	1.82	1.39	6.45	3.86
People
People	Employees	96	98	105	115	109	115	114	99	106	114
	Revenue/emp, $m	0.32	0.32	0.28	0.27	0.21	0.26	0.32	0.34	0.32	0.27
Income, $m
Income, $m	Revenue	31	32	30	32	23	30	36	33	34	31
	Gross margin, %	58.85	59.08	57.34	64.17	61.21	66.22	60.20	55.34	57.27	58.25
	EBT	(3)	(21)	(4)	(4)	(4)	(3)	(5)	(11)	(10)	(6)
	EBT margin, %	(10.03)	(67.33)	(14.39)	(12.47)	(17.92)	(8.91)	(15.17)	(32.74)	(30.56)	(20.36)
	Net income	(3)	(22)	(4)	(4)	(4)	(3)	(6)	(11)	(10)	(6)
	Depreciation	9	7	6	5	4	4	6	6	5	5
Per share, $
Per share, $	Revenue	144.91	117.03	15.24	9.88	6.87	8.80	10.42	9.55	8.82	6.60
	Earnings	(15.50)	(79.28)	(1.72)	(1.10)	(1.30)	(0.80)	(1.60)	(3.10)	(2.65)	(1.35)
	Cash flow	1.52	15.25	1.48	0.70	0.62	0.44	(0.27)	(0.15)	0.05	(0.60)
	Capex	0.00	(1.18)	(0.01)	(0.04)	(0.64)	(1.07)	(1.08)	(1.44)	(0.43)	(0.32)
	Free cash flow	1.52	14.08	1.47	0.66	(0.02)	(0.63)	(1.34)	(1.59)	(0.38)	(0.92)
	Book value	69.46	73.25	15.95	8.96	7.70	7.46	6.29	3.63	1.31	0.63
	Shares, m	0	0	2	3	3	3	3	3	4	5
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.02	0.01	0.17	0.21	0.22	0.17	0.08	0.54	0.33	0.19
	P/B	0.03	0.02	0.16	0.23	0.19	0.20	0.13	1.43	2.23	2.02
	EV/Sales	0.65	0.21	(0.13)	(0.01)	(0.46)	0.00	0.11	0.76	0.54	0.87
	EV/FCF	67.26	1.71	(1.39)	(0.15)	60.94	(0.03)	(0.82)	(4.60)	(12.49)	(6.27)
Cash, $m
Cash, $m	Operating cash flow	0	4	3	2	2	2	(1)	(1)	0	(3)
	Capex	(1)	0	0	0	(2)	(4)	(4)	(5)	(2)	(1)
	Free cash flow	0	4	3	2	0	(2)	(5)	(6)	(1)	(4)
Balance, $m
Balance, $m	Working capital	5	0	15	6	6	7	2	3	3	(11)
	Total debt	23	10	7	9	3	8	8	15	15	15
	Net debt	20	6	(9)	(7)	(16)	(5)	1	7	7	7
	Shareholders’ equity	15	20	31	29	26	25	22	13	5	3
Returns, %
Returns, %	ROA	(7.15)	(52.27)	(9.31)	(7.99)	(9.34)	(5.80)	(11.23)	(22.97)	(26.22)	(19.13)
	ROIC	(6.56)	(4.32)	(9.46)	(8.67)	(24.71)	(13.44)	(12.71)	(27.42)	(50.00)	(28.40)
	ROE	(21.65)	(124.38)	(15.78)	(12.65)	(16.11)	(10.55)	(23.49)	(62.75)	(114.22)	(158.91)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VJET Flyte Aviation, Inc.	$2.1M	— (loss-making)	— (loss-making)	+380.66% (above 0%: growing)	n/m	−26.70% (below 0%: shrinking)	9.62%	(388.13%)	Compare
NUWE Nuwellis, Inc.	$2.0M	— (loss-making)	— (loss-making)	+14.14% (above 0%: growing)	n/m	−51.55% (below 0%: shrinking)	76.08%	(160.94%)	Compare
AFIB Acutus Medical, Inc.	$1.7M	— (loss-making)	— (loss-making)	+204.18% (above 0%: growing)	n/m	+76.40% (above 0%: growing)	14.20%	(3.81%)	Compare
DHAI DIH Holding US, Inc.	$1.6M	— (loss-making)	—	−30.67% (below 0%: shrinking)	n/m	−167.90% (below 0%: shrinking)	50.33%	(33.62%)	Compare
DYNTQ Dynatronics Corporation	$1.2M	— (loss-making)	— (loss-making)	−7.61% (below 0%: shrinking)	n/m	−193.04% (below 0%: shrinking)	24.65%	(1.26%)	Compare
THMO ThermoGenesis Holdings, Inc.	$1.1M	— (loss-making)	5.5×	+6.42% (above 0%: growing)	n/m	+62.12% (above 0%: growing)	43.92%	(20.35%)	Compare
SSKN Strata Skin Sciences, Inc.	$1.0M	— (loss-making)	— (loss-making)	−2.97% (below 0%: shrinking)	n/m	−376.88% (below 0%: shrinking)	61.82%	7.66%
FEED ENvue Medical, Inc.	$950.0K	— (loss-making)	— (loss-making)	−51.62% (below 0%: shrinking)	n/m	+19.75% (above 0%: growing)	(111.30%)	(2,290.38%)	Compare
PFSA PROFUSA, Inc.	$650.0K	0.0×	—	—	n/m	−359.25% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$1.4M	—	—	+6.42%	—	−39.12%	34.29%	(26.98%)

All 149 Medical Devices stocks →

Strata Skin Sciences, Inc. (SSKN) key facts

Concern: Strata Skin Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.7 million, down 8.54% from fiscal 2024.
Strata Skin Sciences, Inc. (SSKN) is a Medical Devices company in the Healthcare sector.
Return on equity was −158.9% and debt-to-equity 5.28.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −11.48 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.